Glioblastoma (GBM)-initiating cells (GICs) are a tumorigenic subpopulation that are resistant to radio/chemotherapies and are the source of recurrence, therefore it is crucial to characterize GICs and find new therapeutic targets. We have successfully established mouse and human GICs, which retain stemness characteristics and tumorigenicity. By comparing their expression profiles with those of parental cells, we have focused on two cell surface membrane proteins, Ceacam1L and Eva1, which were prominently expressed in GICs. We demonstrated that both proteins were involved in GIC characteristics, including self-renewal, stem cell gene expression and side population, and tumorigenesis, indicating that they are potential new therapeutic targets for GBM. In this research highlight, I summarize our recent reports regarding Ceacam1L and Eva1 and then discuss about their potential as GBM therapeutic targets.
Introduction
Gliomas are brain tumors possessing the characteristics of glial cells, astrocytes and oligodendrocytes, and have been classified into four grades (WHO grade I-IV) based on their pathological features. Glioblastoma (GBM) is the most malignant glioma (WHO grade IV), and patients with GBM have a median survival of approximately one year. In spite of tremendous efforts to effectively treat GBM, the overall survival rates of patients with GBM have remained unchanged over the past few decades.
The discovery of GBM-initiating cells (GICs) has had a significant impact on GBM research [1] . GICs have a strong self-renewal capability and express stem cell markers, such as CD133 (also known as Prominin1), Sox2, CD15 (also known as Stage-Specific Embryonic Antigen 1 and Lewis X), and CD49f (also known as integrin α6). In addition, GICs express various types of detoxifying factors, such as ATP-binding cassette (ABC) transporters and Aldehyde dehydrogenase (ALDH), and DNA repair factors, including Bmi1, thereby the cells are more resistant to radio-and chemo-therapies higher than non-GICs [2] [3] [4] .
GICs have also been shown to exploit the signaling pathways that are involved in the maintenance of neural stem cells (NSCs) [2] [3] [4] . It should be noted that NSCs maintain their characteristics as long as they exist in the special microenvironment (niche) in subventricular zone and hippocampus [5, 6] , revealing the important roles of external signals for NSC maintenance. In contrast, since GBM arises in many areas in the brain, GICs may generate their
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preferable niche or employ an unknown mechanism for their maintenance anywhere. It is, therefore, of interest to elucidate the mechanism how GICs maintain their stemness.
It was evident that p53 pathway was the most frequently mutated in GBM and the receptor-tyrosine kinase signaling pathway was also activated in approximately 90% of GBM cases [7, 8] . In fact, we successfully established the mouse GIC lines (mGICs), NSCL61 and OPCL61, by overexpressing an oncogenic HRas L61 in p53-deficient NSCs and oligodendrocyte precursor cells (OPCs), respectively [9, 10] . These mGICs formed transplantable GBM with hypercellularity, pleomorphism, multinuclear giant cells, mitosis and necrosis, even when as few as ten cells were injected into the brains of nude mice. These findings indicated that they were highly enriched in bona fide GICs. Using DNA microarray analysis, we compared the gene expression profiles of mGICs with those of their parental cells and identified genes that increased and decreased in mGICs. By evaluating the candidate genes using human GICs (hGICs) and GBM tissues, we have selected potential GIC-specific genes [9] [10] [11] [12] [13] . Among them, we have characterized two membrane proteins, Epithelial V-like antigen 1 (Eva1, also known as myelin protein zero-like 2) and Carcinoembryonic antigen-related cell adhesion molecule 1 (Ceacam1, also known as CD66a and BGP1), and identified them as novel diagnostic markers and therapeutic targets for GBM [12, 13] . In this review, I summarize our recent findings and discuss how these factors are concerned with the communication between GICs and their niche cells.
Text

Identification and characterization of Ceacam1L as a novel GIC-associated antigen
Ceacam1 consists of 11 splicing variants, seven of which are transmembrane proteins with either a short (Ceacam1S) or long cytoplasmic tail (Ceacam1L) while the others are secretion forms, in human [14] [15] [16] . Transmembrane Ceacam1 exists as a monomer, cis-/trans-homodimer, or cis-/trans-heterodimer with either Ceacam1 splicing variants or other Ceacam family members depending on the cell environment, thereby the intracellular domain of Ceacam1 is either a monomer or a homo-/hetero-dimer, leading to the different signal transmission [15, 16] . It has been shown that Ceacam1 is involved in many different biological functions, including angiogenesis, immune modulation and proliferation [15, 16] . Ceacam1L was also identified as a substrate of both insulin growth factor receptor and epidermal growth factor receptor (EGFR), which are frequently activated in malignant gliomas [17] . On the other hand, the modified Ceacam1 has been shown to act as either an amplifier or attenuator of these receptors in a cell-dependent manner.
We found that both hGICs and mGICs have prominently expressed Ceacam1L, but Ceacam1S was less in these cells. In addition, Ceacam1-positive cells were immunolabeled for CD15 in GBM tissue, suggesting that Ceacam1 is expressed on GICs. Knockdown of Ceacam1 has decreased side population (SP), GIC proliferation and tumorigenesis, whereas overexpression of Ceacam1L has induced massive hemorrhage and increased SP and GIC tumorigenesis, indicating that Ceacam1L plays a crucial role in GICs. To understand molecular mechanism how Ceacam1L regulates GIC characteristics, we have compared the gene expression profile of Ceacam1L-overexpressing NSCs with that of parental cells, and found that Ceacam1L has activated Signal transducer and activator of transcription 3 (STAT3) signaling pathway. When phosphorylated by EGFR, Ceacam1L was shown to activate the proto-oncogene tyrosine-protein kinase Src (c-Src), protein tyrosine phosphatase non-receptor type 6 (PTPN6, also known as src homology region 2 domain-containing phosphatase-1 (SHP1) and PTPN11 (also known as SHP2) and then enhance or prevent the proliferation signals of the receptor in a cell type-dependent manner [15, 18, 19] . We unexpectedly found that the expression of PTPN6, which prevents the Janus kinase (JAK)-dependent STAT3 signaling pathway [20] , was silenced in hGICs, suggesting that a Ceacam1L-dependent negative feedback signal to EGFR was abolished in hGICs. Taken together with the finding that PTPN11 activated EGFR [21, 22] , these data suggest that Ceacam1L acted as an amplifier of both EGFR and STAT3 signaling in hGICs.
Depending on the GIC environment, the cytoplasmic tail of Ceacam1L is either monomer or oligomer. To address which form of the Ceacam1L cytoplasmic tail activates c-Src/STAT3 signaling, we have constructed two chimera proteins, which consist of FLAG, a part of the extracellular domain of the granulocyte colony-stimulating factor receptor, the Ceacam1-transmembrane domain and either the cytoplasmic tail of Ceacam1L or Ceacam1S, FGC1L and FGC1S. We found that FGC1L-overexpressing hGICs have constitutively activated c-Src/STAT3 pathway in the absence of the antibody, whereas the addition of the antibody abolished this activation. FGC1S-overexpressing hGICs did not activate the signaling pathway in either the presence or absence of the antibody. Together, these findings revealed that the monomeric Ceacam1L cytoplasmic tail was involved in the GIC characteristics through the activation of c-Src/STAT3 signaling pathway [12] .
Eva1 is another novel GIC-associated antigen
Eva1 was originally identified as an immunoglobulin superfamily member expressed on the developing thymus epithelial cell membrane and disappeared in the developed one [23] [24] [25] . Eva1 was further shown to be involved in the T cell development through the Eva1-Eva1 homophilic interaction between CD4/CD8 double-positive cells and thymus epithelial cells in the early embryo [23] [24] [25] , however there was no detectable phenotype, including the hematopoietic development, in the Eva1 knockout mice [23] [24] [25] [26] (Ohtsu et al, unpublished observation). Notably, there was no evidence showing that Eva1 was concerned with either tumorigenesis or stemness.
We found that Eva1 was prominently expressed in GICs and GBM, compared with NSCs and other glioma, including anaplastic oligodendroglima and diffuse astrocytoma. Eva1-positive GICs were immunolabeled for Sox2, CD15 and CD49f, which are well-known GIC markers, suggesting that Eva1 is a new marker for GICs. Moreover, knockdown of Eva1 has decreased SP, GIC proliferation and tumorigenesis, whereas overexpression of Eva1 has increased SP and GIC tumorigenesis, identifying Eva1 as an important factor for GICs. To understand molecular mechanism how Eva1 regulates GIC characteristics, we have compared the gene expression profile of Eva1shRNA-overexpressing GICs with that of parental cells, and found that Eva1 has activated a number of signaling pathways, which are involved in stemness and tumorigenesis. Among them, we focused on the Nuclear factor-kappa B (NF-κB) pathway, because Eva1 cytoplasmic tail contains a putative TNF receptor-associated factor 2 (TRAF2) binding site. The receptor-mediated activation of NF-κB has been shown to induce the expression of many genes that regulate inflammation, cell proliferation, immune responses, and tumorigenesis through either canonical or non-canonical signaling pathways [27, 28] . It was demonstrated that RelA/NF-κB1(p50) and RelB/NF-κB2(p52) complexes were key components in the canonical and non-canonical NF-κB signaling pathways respectively, while the receptor-binding protein TRAF2 was involved in both pathways [27] [28] [29] . Using Rela-and Relb-shRNA expression vectors, we have found that RelB knockdown inhibited the NF-κB-dependent luciferase activity in hGICs, their proliferation and tumorigenesis, indicating that non-canonical NF-κB signaling pathway was essential for GIC characteristics. We further demonstrated that Eva1 bound TRAF2 and cellular inhibitor of apoptosis, stabilized the non-canonical NF-κB-inducing kinase (NIK) and induced maturation of p52. In addition, we verified that prognosis of GBM patients with elevated RelB mRNA levels was worse than the others and the expression of relB significantly increased in GBM compared with in lower-grade glioma. NIK, RelB and p52 were indeed accumulated in human GBM tissues. Thus, these data indicated the important role of non-canonical NF-κB signaling pathway in GBM development [13] .
Roles of Ceacam1L and Eva1 as GIC niche factors
Both Ceacam1L and Eva1 are thought to act as homophilic-and heterophilic-binding proteins [14] [15] [16] [17] 24] , thereby GICs may be influenced by the intercellular interaction with their surrounding cells that express Ceacam1L, Eva1 or unknown factors, and vice versa. Indeed, we found that GICs closely associated with CD68+ cells (e.g. microglia and neutrophil), which expressed Ceacam1 and STAT3 that is required for their motility, and the retinoic acid receptor-related orphan receptor gamma t (RORγT)+ helper T (Th17) cells, which expressed Eva1 and the RelB that was necessary for the induction of RORγT, in GBM tissues. These findings suggest that the Eva1-and Ceacam1L-dependent reciprocal relationship between GICs and their surrounding cells plays crucial parts in the + cells. Both non-canonical NF-κB and STAT3 signaling pathways not only concern with GIC characteristics and tumorigenesis, but also induce Th17 differentiation and CD68 + cell proliferation, respectively. maintenance of GICs and their niche formation [12, 13] .
It should be noted that Ceacam1 is one of immune-checkpoint factors, such as programmed death 1 (PD-1)/PD-L1, cytotoxic T-lymphocyte-associated protein 4 and T-cell immunoglobulin domain and mucin domain 3 (TIM-3) [30] [31] [32] . For instance, it has been shown that Ceacam1-homophilic binding between natural killer (NK) cells and melanoma cells abolished NK-dependent cytotoxicity against cancer cells [33] . The binding of Ceacam1 with TIM3 was also demonstrated to induce T cell exhaustion in colorectal cancer [34] . Thus, these findings suggest that Ceacam1-targeting not only increases cytotoxicity of immune cells in GBM but also prevents GIC tumorigenicity.
Cross-talk of Ceacam1L and Eva1 signaling pathways
Interestingly, it has been demonstrated that the inflammatory cytokine interleukin 6 (IL-6) stimulates secretion of IL-6 and IL-7 through STAT3 activation in fibroblasts. In turn, the combination of IL-6 and IL-7 induces the expression of IL-6 and IL-17 in Th17 cells. IL-6 and IL-17 further stimulate secretion of IL-6 through the activation of NF-κB signaling in the fibroblasts. Thus, the inflammatory signals can be amplified between fibroblasts and Th17 cells by activating STAT3 and NF-κB signaling pathways [35, 36] . In the similar way, Ceacam1 and Eva1 may amplify the inflammatory signals in GICs by interacting with CD68+ cells and Th17 cells, because Eva1 positively regulates the expression of Ceacam1L while STAT3 likely binds Eva1 promoter. Thus, these data suggest that targeting Eva1 and Ceacam1L may eradicate GBM by preventing functions of both GICs and their niche cells.
Conclusions
We demonstrated that GICs prominently expressed cell-surface membrane proteins Ceacam1L and Eva1, compared with their parental cells, and that these proteins played indispensable roles for GIC characteristics and tumorigenesis by activating STAT3 and non-canonical NF-κB signaling pathways. Since these factors were also expressed on the GIC surrounding cells, such as microglia andTh17, it is likely that GICs and their surrounding cells have a benefit mutually by associating intercellularly. Therefore, Eva1-or Ceacam1L-dependent intercellular binding of GICs and their niche cells would be new promising targets for GBM therapy.
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